Validated immunology target program
Autoimmune disorders
Key Facts
About Genesis Therapeutics
Genesis Therapeutics is a private, AI-native drug discovery company pioneering the use of generative AI and physics-based models to invent novel small molecule drugs. Its core technology is the GEMS (Genesis Exploration of Molecular Space) platform, anchored by foundation models like the 3D diffusion model Pearl, which is used to design compounds against challenging targets. The company has secured significant upfront payments through multi-target collaborations with partners like Gilead and Incyte, while also advancing a wholly-owned pipeline in oncology and immunology. Genesis operates at the intersection of cutting-edge AI research and experimental biology, with teams in the Bay Area, New York City, and a wet lab in San Diego.
View full company profileTherapeutic Areas
Other Autoimmune disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| TNB-512 | Tenacia Biotechnology | Phase 1 |
| Biosimilar Candidate | MSN Laboratories | Pre‑clinical |
| TYK2 Pseudokinase Inhibitor | A2A Pharma | Preclinical |
| Marine Membrane Lipid Extract(s) | Arctic Bioscience | Pre-clinical |
| NAMPT - Autoimmune | Remedy Plan Therapeutics | Discovery |
| LZB-201 | Lazuline Biotech | Preclinical |
| Autoimmunity Diagnostics | Eurobio | Commercial |